Amgen Inc.Long
AMGN Long Term Long
Top pharma pick right now other than BMY. P/E 13.11 with forecasted 6-7% earnings growth and an EPS yield of 7.62%.
Historic Norm P/E 18.89
^ 10 Y = 14.50
^ 5 Y = 14.25
3.49% Div payer.
Valuation estimate based on 2023 forecasted EPS (19.11) and P/E of 14.25 = $272.32
Historic Norm P/E 18.89
^ 10 Y = 14.50
^ 5 Y = 14.25
3.49% Div payer.
Valuation estimate based on 2023 forecasted EPS (19.11) and P/E of 14.25 = $272.32
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.